Shivshankar Thanigaimani
Overview
Explore the profile of Shivshankar Thanigaimani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
321
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pegler A, Thanigaimani S, Pai S, Morris D, Golledge J
Vasc Endovascular Surg
. 2024 Oct;
59(3):277-287.
PMID: 39387438
Objective: Peripheral artery disease affects approximately 250 million people globally. Multiple randomised controlled trials have compared bypass and endovascular interventions but the optimum revascularisation approach remains unclear. The recently published...
2.
Thanigaimani S, Neale R, Waterhouse M, Moxon J, Yeap B, Norman P, et al.
JVS Vasc Sci
. 2024 Sep;
5:100208.
PMID: 39219591
Objective: We examined the associations between 25-hydroxy vitamin D (25(OH)D) concentration and the diagnosis and growth of abdominal aortic aneurysm (AAA). Methods: AAA cases and healthy controls were recruited from...
3.
Alahakoon C, Thanigaimani S, Singh T, Drovandi A, Charles J, Fernando M, et al.
PLoS One
. 2024 Jul;
19(7):e0302186.
PMID: 38968185
Introduction: Minor amputation is commonly needed to treat diabetes-related foot disease (DFD). Remoteness of residence is known to limit access to healthcare and has previously been associated with poor outcomes....
4.
Wong S, Thanigaimani S, Charles J, Whaleboat D, Golledge J
J Clin Med
. 2024 Jun;
13(11).
PMID: 38893050
This retrospective analysis of an ongoing prospective cohort study aimed to assess the outcome of revascularisation for treating lifestyle-limiting intermittent claudication caused by peripheral artery disease (PAD) in Aboriginal and...
5.
Thanigaimani S, Sun D, Ahmad U, Anning N, Tian K, Golledge J
Eur J Vasc Endovasc Surg
. 2024 May;
68(2):246-254.
PMID: 38754723
Objective: The aim of this study was to compare the efficacy of different endovascular revascularisation procedures for treating chronic limb threatening ischaemia (CLTI) using network meta-analysis (NMA). Data Sources: The...
6.
Tian K, Thanigaimani S, Gibson K, Golledge J
Eur J Vasc Endovasc Surg
. 2024 Mar;
68(2):180-187.
PMID: 38537880
Objective: Whether angiotensin II blockade is an effective medical treatment for abdominal aortic aneurysms (AAAs) has not been established. This systematic review and meta-analysis aimed to determine the association between...
7.
Rabia B, Thanigaimani S, Golledge J
Cardiovasc Pathol
. 2024 Mar;
70:107629.
PMID: 38461960
Background: Abdominal aortic aneurysm is a weakening and expansion of the abdominal aorta. Currently, there is no drug treatment to limit abdominal aortic aneurysm growth. The glycocalyx is the outermost...
8.
Golledge J, Thanigaimani S, Barratt K, Fadini G
Diabetes Metab Res Rev
. 2023 Aug;
40(3):e3703.
PMID: 37563926
Diabetes is a key risk factor for ischaemic foot disease, which causes pain, tissue loss, hospital admission, and major amputation. Currently, treatment focuses on revascularisation, but many patients are unsuitable...
9.
Golledge J, Thanigaimani S, Powell J, Tsao P
Eur Heart J
. 2023 Jun;
44(29):2682-2697.
PMID: 37387260
Abdominal aortic aneurysm (AAA) causes ∼170 000 deaths annually worldwide. Most guidelines recommend asymptomatic small AAAs (30 to <50 mm in women; 30 to <55 mm in men) are monitored...
10.
Thanigaimani S, Jin H, Ahmad U, Anbalagan R, Golledge J
Diabetes Metab Res Rev
. 2023 Jun;
39(5):e3670.
PMID: 37277960
Introduction: This study examined the relative efficacy of growth factor therapies in healing diabetes-related foot ulcers (DFU). Methods: PubMed and Cochrane databases were searched for randomized controlled trials testing growth...